Long-Term Extension of the Multinational, Double-Blind, Placebo Controlled Studies PDY6045 and PDY6046 to Document the Safety of Teriflunomide When Added to Treatment With Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis With Relapses.

Trial Profile

Long-Term Extension of the Multinational, Double-Blind, Placebo Controlled Studies PDY6045 and PDY6046 to Document the Safety of Teriflunomide When Added to Treatment With Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis With Relapses.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2012

At a glance

  • Drugs Teriflunomide (Primary) ; Glatiramer acetate; Interferon beta
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Apr 2012 Last checked against European Clinical Trials Database record.
    • 10 Jan 2012 Actual patient number is 182 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top